Estrella Immunopharma, Inc.
ESLA Nasdaq
SEC CIK 1844417
Follow Estrella Immunopharma
Weekly email: filings, results, news
Net income
−$2.3M
+58.4% vs same quarter last year
EPS, diluted
−$0.05
+66.7% vs same quarter last year
Operating cash flow
−$1.8M
−329.2% vs same quarter last year
Operating income
−$2.1M
+62.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$13.1M |
| FY24 | −$7.3M |
| FY23 | −$11.1M |
| FY22 | −$996.1K |
| FY21 | −$247.7K |
| FY20 | - |
News
No stories filed under Estrella Immunopharma yet - coverage appears here as the news feed clusters it.